The following exposure cohorts were compared:

<ul>
<li><strong>SGLT2i-BROAD:</strong> New users of any SGLT2i with prior T2DM (broad definition)</li>
<li><strong>Canagliflozin-BROAD:</strong> New users of canagliflozin with prior T2DM (broad definition)</li>
<li><strong>Dapagliflozin-BROAD:</strong> New users of dapagliflozin with prior T2DM (broad definition)</li>
<li><strong>Empagliflozin-BROAD:</strong> New users of empagliflozin with prior T2DM (broad definition)</li>
<li><strong>DPP-4i-BROAD:</strong> New users of any DPP-4i with prior T2DM (broad definition)</li>
<li><strong>GLP-1a-BROAD:</strong> New users of any GLP-1a with prior T2DM (broad definition)</li>
<li><strong>SU-BROAD:</strong> New users of any SU with prior T2DM (broad definition)</li>
<li><strong>TZDs-BROAD:</strong> New users of any TZD with prior T2DM (broad definition)</li>
<li><strong>Insulin-BROAD:</strong> New users of insulin with prior T2DM (broad definition)</li>
<li><strong>Metformin-BROAD:</strong> New users of metformin with prior T2DM (broad definition)</li>
<li><strong>Insul. AHAs-BROAD:</strong> New users of insulinotropic AHAs with prior T2DM (broad definition)</li>
<li><strong>Other AHAs-BROAD:</strong> New users of other AHAs with prior T2DM (broad definition)</li>
<li><strong>SGLT2i-NARROW:</strong> New users of any SGLT2i with prior T2DM (narrow definition)</li>
<li><strong>Canagliflozin-NARROW:</strong> New users of canagliflozin with prior T2DM (narrow definition)</li>
<li><strong>Dapagliflozin-NARROW:</strong> New users of dapagliflozin with prior T2DM (narrow definition)</li>
<li><strong>Empagliflozin-NARROW:</strong> New users of empagliflozin with prior T2DM (narrow definition)</li>
<li><strong>DPP-4i-NARROW:</strong> New users of any DPP-4i with prior T2DM (narrow definition)</li>
<li><strong>GLP-1a-NARROW:</strong> New users of any GLP-1a with prior T2DM (narrow definition)</li>
<li><strong>SU-NARROW:</strong> New users of any SU with prior T2DM (narrow definition)</li>
<li><strong>TZDs-NARROW:</strong> New users of any TZD with prior T2DM (narrow definition)</li>
<li><strong>Insulin-NARROW:</strong> New users of insulin with prior T2DM (narrow definition)</li>
<li><strong>Metformin-NARROW:</strong> New users of metformin with prior T2DM (narrow definition)</li>
<li><strong>Insul. AHAs-NARROW:</strong> New users of insulinotropic AHAs with prior T2DM (narrow definition)</li>
<li><strong>Other AHAs-NARROW:</strong> New users of other AHAs  with prior T2DM (narrow definition)</li>
</ul>
  
These specific ingredients are included in the drug classes mentioned above:
<ul>
<li><strong>SGLT2 inhibitors:</strong> canagliflozin, dapagliflozin, empagliflozin</li>
<li><strong>DPP-4 inhibitors:</strong> alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin</li>
<li><strong>GLP-1 agonists:</strong> albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide</li>
<li><strong>Sulfonylureas:</strong> acetohexamide, carbutamide, chlorpropamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glyburide, glymidine, tolazamide, tolbutamide</li>
<li><strong>TZDs:</strong> pioglitazone, rosiglitazone, troglitazone</li>
<li><strong>Insulinatropic AHAs:</strong> alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glyburide, glymidine, tolazamide, tolbutamide, nateglinide, repaglinide</li>
<li><strong>Other AHAs:</strong> arcabose, bromocriptine, miglitol, nateglinide, repaglinide</li>
</ul>

Type 2 diabetes mellitus definitions:
<ul>
<li><strong>Broad definition:</strong> Diagnosis of type 2 diabetes mellitus with no diagnosis of type 1 diabetes mellitus or secondary diabetes mellitus on or before index drug exposure
<li><strong>Narrow defintion:</strong> Diagnosis of type 2 diabetes mellitus with no diagnosis of type 1 diabetes mellitus or secondary diabetes mellitus on or before or after index drug exposure, and excludes patients taking insulin monotherapy before index drug exposure and excludes patients under 40 years of age at index drug exposure</li>
</ul>

Key - T2DM: type 2 diabetes mellitus; SGLT2i: sodium glucose co-transporter 2 inhibitor; DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1a: Glucagon-like peptide-1 agonist; SU: sulfonylureas; TZD: thiazolidinedione; Insul. AHA: insulinotropic antihyperglycemic agent; AHA: antihyperglycemic agent